Your browser doesn't support javascript.
loading
Questioning the "Ease" in disease: Was living with HIV a burden or boost during the first wave of Covid-19 in France? A qualitative study (COVIDHIV).
Roucoux, Guillaume; Thonon, Frédérique; Zucman, David; Rey, David; Abgrall, Sophie; Eriksson, Lars E; Préau, Marie; Michels, David; Chéret, Antoine; Duracinsky, Martin.
Afiliação
  • Roucoux G; ECEVE, UMR-S 1123, Inserm, Université Paris Cité, Paris, France.
  • Thonon F; Patient-Reported Outcomes Research (PROQOL), Unité de Recherche Clinique en Economie de la Santé (URC-ECO), Hôpital Hôtel-Dieu, AP-HP, Paris, France.
  • Zucman D; ECEVE, UMR-S 1123, Inserm, Université Paris Cité, Paris, France.
  • Rey D; Patient-Reported Outcomes Research (PROQOL), Unité de Recherche Clinique en Economie de la Santé (URC-ECO), Hôpital Hôtel-Dieu, AP-HP, Paris, France.
  • Abgrall S; Foch Hospital, Suresnes, France.
  • Eriksson LE; Trait d'Union-Strasbourg University Hospitals, Strasbourg, France.
  • Préau M; Hôpital Antoine Béclère, Service de Médecine Interne, Clamart, France.
  • Michels D; UVSQ, INSERM U1018, CESP, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Chéret A; Karolinska Institute, Solna, Sueden.
  • Duracinsky M; Inserm Unit 1296 « Radiations: Defense, Health, Environment ¼, Lyon, France.
PLoS One ; 19(3): e0295223, 2024.
Article em En | MEDLINE | ID: mdl-38452028
ABSTRACT

INTRODUCTION:

Clinical research has focused on risk factors and treatment for severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), particularly in people with a comorbidity including the human immunodeficiency virus (HIV), but little attention has been paid to the care pathway. This article aims to show how living with HIV may have been a biopsychosocial burden or boost in care pathways for Covid-19.

METHOD:

People living with HIV (PLHIV) from 9 clinical centers were invited to participate in this qualitative study. The sampling was purposive with a maximum variation in their sociodemographic profiles. Semi-structured interviews were conducted until data saturation, then coded for thematic analysis, using an inductive general approach.

RESULTS:

We interviewed 34 PLHIV of which 20 had SARS-COV-2 once. They were 24 males, 26 born in France; median age 55. Twenty had a CD4 number above 500, and all were on antiretroviral therapy (ART). HIV appeared as a burden when Covid-19 symptoms reminded HIV seroconversion, fear of contamination, and triggered questions about ART effectiveness. HIV was not considered relevant when diagnosing Covid-19, caused fear of disclosure when participants sought SARS-COV-2 testing, and its care in hospitals was disrupted by the pandemic. ART-pill fatigue caused avoidance for Covid-19 treatment. As a boost, living with HIV led participants to observe symptoms, to get advice from healthcare professionals, and screening access through them. Some participants could accept the result of screening or a clinical diagnosis out of resilience. Some could consider ART or another drug prescribed by their HIV specialist help them to recover from Covid-19.

CONCLUSION:

Living with HIV could function as a burden and/or a boost in the care pathways for Covid-19, according to patients' relationship to their HIV history, comorbidities and representation of ART. Covid-19 in PLHIV needs further qualitative study to gain a more comprehensive assessment of the pandemic's consequences on their lives and coping strategies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / COVID-19 Limite: Humans / Male / Middle aged Idioma: En Revista: PLoS One Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / COVID-19 Limite: Humans / Male / Middle aged Idioma: En Revista: PLoS One Ano de publicação: 2024 Tipo de documento: Article